

## Product Information

### p38-MAPK inhibitor VX-745, Purity $\geq 98\%$

**Cat. No.:** X23-10-ZQ902

**Size:** 5 mg; 10 mg; 25 mg; 50 mg; 100 mg

**MDL:** MFCD09834070

**CAS Number:** 209410-46-8

**Compound CID:** 3038525


**Synonym:** 209410-46-8; VX-745; Neflamapimod;

5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6*H*-pyrimido[1,6-*b*]pyridazin-6-one;

VX 745; VX745;

5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-*b*]pyridazin-6-one;

p38-MAPK inhibitor



**This product is for research use only and is not intended for diagnostic use.**

### Product Information

<b>Description</b>	VX-745, soluble in DMSO and insoluble in ethanol and water, targets the ATP-binding site of the kinase, thereby preventing phosphorylation of downstream substrates. It targets p38 $\alpha$ and p38 $\beta$ .
<b>Molecular Weight</b>	436.3
<b>Molecular Formula</b>	C <sub>19</sub> H <sub>9</sub> Cl <sub>2</sub> F <sub>2</sub> N <sub>3</sub> OS
<b>Targets</b>	p38 $\alpha$ : 10 nM; p38 $\beta$ : 220 nM
<b>IUPAC Name</b>	5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6- <i>b</i> ]pyridazin-6-one
<b>InChI</b>	InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H
<b>InChI Key</b>	VEPKQEUBKLEPRA-UHFFFAOYSA-N
<b>Canonical SMILES</b>	C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C(=C4)F)F)Cl
<b>Form</b>	Lyophilized powder
<b>Purity</b>	$\geq 98\%$
<b>Solubility</b>	DMSO: 15 mg/mL (34.38 mM); Water: Insoluble; Ethanol: Insoluble
<b>Identity</b>	Confirmed by NMR/HPLC/MS.
<b>Stability</b>	The product is stable for three years when stored at the recommended temperature in lyophilized powder.
<b>Applications</b>	VX-745 is used to examine the selective inhibition of p38 $\alpha$ MAP kinase for therapeutic potential in



neuroinflammation and neurodegenerative disorders.

---

**Storage**

Store at -20°C.

---